An official website of the United States government
Augment current and future human cohorts with more advanced, longitudinal immunological profiling (e.g. Cytof) to enable precision medicine research and to better understand the roles of the different arms of the central nervous system and peripheral immunity in brain aging and AD.
2024 RFA-AG-15-018: Immune and Inflammatory Mechanisms in Alzheimer's Disease (R01) 1.G Achieved Augment current and future human cohorts with more advanced, longitudinal immunological profiling (e.g. Cytof) to enable precision medicine research... DN 2018 AD Summit: 1H and 2E Population Studies and Precision Medicine AMP-AD 2.0 Precision Medicine Approach to Target and Biomarker Discovery Immune Cells in Alzheimer’s Disease and Related Dementias in the Jackson Heart Study Columbia ADRC Neuroimmunology Core
- Provide supplemental funding to support longitudinal immunologic profiling to existing and newly launched mid-life and aging cohorts with rich-phenotypic data on brain health.
Summary of Key Accomplishments
The second phase of the Accelerating Medicines Partnership® for AD (AMP AD 2.0) will conduct longitudinal immune profiling in a well-phenotyped cohort of diverse participants to establish individual trajectories of immunological aging and their relationship to AD. It will develop a rich data/analytical resource that will capture a population-based sample of trajectories of immunological aging. These data will be made available to the research community via the NIA-supported AD Knowledge Portal.
The key accomplishments summary is current as of July 2022.